Werth Ventures

Peter Werth, who founded and later sold the generic-drug licensing firm ChemWerth, remains the sole investment decision-maker. The office does not list a separate CIO or external investment committee. His personal experience navigating FDA approval processes and international pharmaceutical licensing directly shapes the firm's deal evaluation, particularly for therapeutics investments.

The office relies on Peter Werth's decades-long network in pharmaceutical licensing and the Connecticut bioscience community, including proximity to Yale University's research ecosystem. It does not participate in the traditional venture-capital pitch-circuit, preferring introductions through domain-expert intermediaries and scientists who have commercialized prior drug candidates.

It is a pure single family office. Werth Ventures does not accept outside limited partners, does not charge management fees, and does not market itself to institutional allocators. All capital is Werth family capital, deployed at the discretion of Peter Werth without the fundraising-cycle constraints of a venture firm.

The office is overwhelmingly direct-investment focused. There is no public evidence of significant fund-of-funds activity or LP commitments to unaffiliated venture firms. When it co-invests alongside other capital sources, it does so on a deal-by-deal basis as a direct participant, not through a pooled vehicle.

The firm concentrates on early-stage to Series A opportunities, often as the first institutional capital into a company. Peter Werth's operating background means the office is comfortable with pre-revenue biotech and deep-tech startups where the primary asset is intellectual property rather than commercial traction. Later-stage positions, such as the Arvinas holding, have sometimes originated from very early bets that were held through IPO.

The office appears to avoid consumer internet, e-commerce, and traditional brick-and-mortar retail — sectors far removed from the pharmaceutical and regulated-industry expertise that drives its sourcing. There is also no record of real estate, energy, or infrastructure investments within the Werth Ventures portfolio, though the family foundation holds unrelated real assets.

The two are legally separate. The Werth Family Foundation is a philanthropic entity that funds educational scholarships and community projects in Connecticut, most visibly at the University of Connecticut. Investment decisions are made inside Werth Ventures and are structurally walled off from foundation governance. No foundation grants flow to portfolio companies.